Daratumumab depletes CD38(+) immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma

Daratumumab targets CD38-expressing myeloma cells through a variety of immune-mediated mechanisms (complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity, and antibody-dependent cellular phagocytosis) and direct apoptosis with crosslinking. These mechanisms may also target...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Krejcik, Jakub, Casneuf, Tineke, Nijhof, Inger S., Verbist, Bie, Bald, Jaime, Plesner, Torben, Syed, Khaja, Liu, Kevin, van de Donk, Niels W. C. J., Weiss, Brendan M., Ahmadi, Tahamtan, Lokhorst, Henk M., Mutis, Tuna, Sasser, A. Kate
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2016
Assuntos:
Immunobiology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4957162/
https://ncbi.nlm.nih.gov/pubmed/27222480
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-12-687749
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados